Categories: News

EverBridge Group and Cosmotec Forge Landmark Partnership

SHANGHAI, Sept. 15, 2025 /PRNewswire/ — EverBridge Group announced an Exclusive Commercialization Partnership with Cosmotec Inc. (a Wholly Owned Subsidiary of M3, Inc.; TSE: 2413) for the Japanese market.

- Advertisement -

This strategic collaboration underscores EverBridge Group’s leadership in proprietary R&D, stringent regulatory compliance, and value-driven ecosystem collaboration, marking a significant milestone in its global expansion strategy, further amplifying its international influence.

- Advertisement -

Simultaneously, the partnership underscores Cosmotec’s best-in-class digital commercialization platform, which accelerates market access for international medical devices and enables targeted engagement with clinical end-users.

- Advertisement -

“EverBridge Group’s portfolio demonstrates outstanding clinical efficiency and user-friendly design, aligning perfectly with Japanese physicians’ pursuit of advanced therapeutic solutions,” stated Suguru Ominato, CEO of Cosmotec. “By integrating M3’s academic platforms with our localized commercialization expertise, we will accelerate the adoption of these devices across the Japanese market.”

- Advertisement -

“Cosmotec’s digital commercialization model delivers both efficiency and accessibility, which aligns perfectly with our vision for equitable healthcare innovation,” said Jay Wang, CEO of EverBridge Group. “By navigating Japan’s rigorous technical and regulatory landscape, this partnership not only delivers transformative solutions to patients but also enhances our global R&D synergy. Lowering barriers to advanced care through innovation and ecosystem collaboration remains central to our globalization journey.”

- Advertisement -

About EverBridge Group

- Advertisement -

EverBridge Group is a leading medical technology group in Asia, committed to providing global customers with cutting-edge, high-quality, and affordable medical technologies. Our rapidly expanding product portfolio covers three major therapeutic areas: peripheral vascular, neuroscience, and oncology. Supported by Six specialized R&D and lean production centers, we offer top-tier OEM/ODM services in areas including balloons, catheters, stents, surface engineering, and active medical devices.

- Advertisement -

We collaborate extensively with outstanding enterprises worldwide, building a bridge for medical technology innovation between Asia and the rest of the world. Our goal is to offer healthcare professionals and patients globally better treatment options through advanced and accessible solutions.

- Advertisement -

For more information, please visit the official website: www.everbridgemed.com

- Advertisement -

Contact: Ann Chencommunications@everbridgemed.com

- Advertisement -

Photo – https://mma.prnewswire.com/media/2764432/DSC02892.jpg

- Advertisement -

View original content:https://www.prnewswire.com/in/news-releases/everbridge-group-and-cosmotec-forge-landmark-partnership-302553681.html

- Advertisement -

Recent Posts

Charles Winslow Completes Annual Internal Strategic Review at Lumena Intelligent Alliance Office

Jersey City, NJ, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Lumena Intelligent Alliance Office confirmed that…

3 hours ago

DebitMyData Human Energy Grid: The Trillion-Dollar Infrastructure Play That Genesis Executive Order Validates

DebitMyData™ Logo FORT LAUDERDALE, Fla., Dec. 25, 2025 (GLOBE NEWSWIRE) -- DebitMyData, Inc., having oversubscribed…

3 hours ago

Yoolax Announces a Milestone 2025 of Growth, Smart Innovation, and Customer Trust

HongKong, Dec. 25, 2025 (GLOBE NEWSWIRE) -- Yoolax, a leading brand in the motorized window…

3 hours ago

Profound Medical Corp. Announces Upsize of Private Placement

TORONTO, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the…

6 hours ago

ImmuCell Announces Strategic Focus on First Defense After Receiving an FDA Incomplete Letter for Re-Tain

December 24, 2025 13:05 ET  | Source: ImmuCell Corporation PORTLAND, Maine, Dec. 24, 2025 (GLOBE…

6 hours ago

WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective December 29, 2025

Hangzhou, China, Dec. 24, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK)…

6 hours ago